Virpax Explores MET Technology for Intranasal COVID-19 Vaccine Development
Virpax Explores MET Technology for Intranasal COVID-19 Vaccine Development Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative, non-addictive treatments for pain…
UroGen Pharma Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
UroGen Pharma Reports Inducement Grants Under Nasdaq Rule 5635(c)(4) UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotechnology company focused on developing and commercializing innovative therapies for urothelial and specialty cancers,…
NovaBay Pharmaceuticals Announces Special Stockholders Meeting
NovaBay Pharmaceuticals Announces Special Stockholders Meeting NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) has officially announced the scheduling of a virtual Special Meeting on April 16, 2025.…
Sensorion Completes Enrollment in NOTOXIS Phase 2a Trial
Sensorion Completes Patient Enrollment in NOTOXIS Phase 2a Clinical Trial of SENS-401 for Cisplatin-Induced Ototoxicity Prevention Sensorion, a pioneering clinical-stage biotechnology company focused on the development of innovative therapies for…
ENCell’s EN001 Granted FDA Orphan Drug Status for Charcot-Marie-Tooth Disease
ENCell’s EN001 Granted FDA Orphan Drug Designation for Charcot-Marie-Tooth Disease ENCell, a pioneering biopharmaceutical company specializing in cell and gene therapy CDMO and novel drug development, announced that its investigational…
Arrowhead Highlights Clinical-Stage RNAi Therapies for Obesity and Metabolic Diseases
Arrowhead Highlights Clinical-Stage RNAi Therapies for Obesity and Metabolic Diseases Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) recently showcased promising preclinical data supporting the advancement of two first-in-class, RNA interference (RNAi)-based investigational…
Tris Pharma Reports Positive Phase 3 Results for Cebranopadol in Acute Pain
Tris Pharma Reports Positive Phase 3 Results for Cebranopadol in Acute Pain Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company dedicated to developing innovative pain management therapies, has announced positive…
Frazier Life Sciences Names Gerald Nepom as Senior Advisor
Frazier Life Sciences Names Gerald Nepom as Senior Advisor Frazier Life Sciences (FLS), a premier investment firm dedicated to advancing groundbreaking therapeutics, has appointed Gerald (Jerry) Nepom, M.D., Ph.D., as…
bioAffinity Cuts $4M in Costs to Boost CyPath® Lung Sales
bioAffinity Cuts $4M in Costs to Boost CyPath® Lung Sales bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company dedicated to advancing noninvasive diagnostic solutions for early-stage lung cancer and…
Ventus Therapeutics Showcases Caspase-4/5 as Key Therapeutic Targets in Nature Reviews Immunology
Ventus Therapeutics Showcases Caspase-4/5 as Key Therapeutic Targets in Nature Reviews Immunology Ventus Therapeutics, a clinical-stage biopharmaceutical company focused on advancing innovative small-molecule therapies for immunological, inflammatory, and neurological disorders,…
NeuPath Health Launches Arthrosamid® for Knee Osteoarthritis
NeuPath Health Launches Arthrosamid® for Knee Osteoarthritis NeuPath Health Inc. (TSXV: NPTH) (“NeuPath” or the “Company”), a leading provider of chronic pain treatment through its extensive network of clinics, has…
Xeris Biopharma Reports Record Q4 and Full-Year 2024 Results, Sets 2025 Guidance
Xeris Biopharma Reports Record Q4 and Full-Year 2024 Results, Sets 2025 Guidance Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a rapidly growing biopharmaceutical company dedicated to improving patient lives by developing…